Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial For Psoriasis

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has obtained approval to begin Phase 2 clinical testing of PH-10, the company’s topical drug for dermatology, for the treatment of psoriasis. The study is designed to evaluate efficacy of PH-10 in a total of twenty-five subjects with moderate to severe forms of the disease. In the study, PH-10 will be applied twice weekly for up to twelve weeks to each subject’s psoriatic plaque areas. [click link for full article]

More: continued here

Filed under: Dermatology on November 18th, 2007